reports
Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December. 7ᵗʰ Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Analyst-led fireside chat: 3:00 p.m. ET Citi 2024 Global Healthcare Conference D...
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Pr...
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following...
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for ...
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of ...
Wave Life Sciences Highlights Growing Pipeline at Research Day, includ...
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Recent proof-of-mechanism data for WVE-006 unlocked Wave’s best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB ar...
Wave Life Sciences Ltd: 2 directors
Two Directors at Wave Life Sciences Ltd sold/sold after exercising options 299,310 shares at between 13.671USD and 15.000USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades b...
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Hum...
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver disease A single subcutaneous dose of WVE-006 in the first two patients with homozygous “ZZ” AATD resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing wi...
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesda...
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024 Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it will host a virtual Research Day on Wednesday, Octo...
Wave Life Sciences Announces Closing of Upsized Public Offering of Ord...
Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it closed its previously announced underwritten public offering, and that the underwriters exercised in full their option to purchase an additional 3,750,000 of its ordinary share...
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines ...
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan 8th Annual Genetic Medicines Conference in New York City on Tuesday, October 1, 2024, at 1:00 p.m. ET. A live webcast of this presentation ...
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordi...
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shar...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave int...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Cli...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of WVE-N531 in myogenic stem cells and reg...
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for...
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 are on track for 3Q 2024 In previous Part A trial, WVE-N531 achieved industry-leading exon skipping of 53% and muscle tissue concentrations that were approximately 20-30 times higher than those reported by exon skipping technologies leveraging muscle delivery conjugates CAMBRIDGE, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Wave Li...
Wave Life Sciences Reports Second Quarter 2024 Financial Results and P...
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update Successful clinical translation of Wave’s RNA medicines platform in HD patients with WVE-003 provides further validation of Wave’s proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; p...
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for...
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024 CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company’s second quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the W...
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-...
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort Statistically significant correlation between mHTT lowering and slowing of caudate atrophy - an imaging biomarker pr...
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel...
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual subcutaneous administration Presentations at the RNA Editing Summit to review how Wave is advancing a high-value pipeline of wholly owned RNA editing therapeutics for mRNA correction and ...
- Research Team ACF
Regenerative Healthcare - Stem Cells & ALS Thematic 10062024
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
NOVN NOVARTIS AG
CG3 CELGENE CORPORATION
QURE UNIQURE NV
MRK MERCK & CO. INC.
JNJ JOHNSON & JOHNSON
GILD GILEAD SCIENCES INC.
CYTK CYTOKINETICS INCORPORATED
BMY BRISTOL-MYERS SQUIBB COMPANY
BIIB BIOGEN INC.
BCLI BRAINSTORM CELL THERAPEUTICS
SAN SANOFI
4523 EISAI CO. LTD.
IONS IONIS PHARMACEUTICALS INC.
WVE WAVE LIFE SCIENCES
PFE PFIZER INC.
ABBV ABBVIE INC.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
NOVO NOVO NORDISK A/S-B
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conf...
Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 2024 Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024, at 7:30 a.m. ET. A live webcast of this presentation will be available on the Investor Relations page o...
Wave Life Sciences Reports First Quarter 2024 Financial Results and Pr...
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, fat loss with no loss of muscle mass, and curtailed rebound weight gain upon cessation of semaglutide, with potential for dosing 1 – 2 times per year Continued momentum in GSK collaboration; adva...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.